MedTrace Logo

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

NCT04287309 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-02-27

No results posted yet for this study

Summary

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy involved in CNS. 20 patients were enrolled. Primary objective is to explore the safety. The secondary objective is to explore the efficacy.

Conditions

  • Hematological Malignancy

Interventions

OTHER

CAR-T cells

CD19 targeted CAR-T treatment

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Eligibility

Min Age
3 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2022-02-28
Completion
2023-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04287309 on ClinicalTrials.gov